A report higher Q4 revenues and lifts its 2026 outlook, yet the stock slips as margins narrow across key business segments.
Agilent Technologies, Inc. ( A ) Q4 2025 Earnings Call November 24, 2025 4:30 PM EST Company Participants Tejas Savant Padraig McDonnell - CEO, President & Director Adam Elinoff - Senior VP, CFO & Principal Financial Officer Rodney Gonsalves - Principal Accounting Officer, VP & Corporate Controller Simon May - SVP & President of LDG Angelica Riemann - Senior VP & President of Agilent CrossLab Group Mike Zhang - Senior VP & President of Applied Markets Group Conference Call Participants Tycho Peterson - Jefferies LLC, Research Division Patrick Donnelly - Citigroup Inc., Research Division Daniel Leonard - UBS Investment Bank, Research Division Douglas Schenkel - Wolfe Research, LLC Brandon Couillard - Wells Fargo Securities, LLC, Research Division Vijay Kumar - Evercore ISI Institutional Equities, Research Division Jack Meehan - Nephron Research LLC Daniel Brennan - TD Cowen, Research Division Michael Ryskin - BofA Securities, Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Luke Sergott - Barclays Bank PLC, Research Division Presentation Operator Good afternoon.
Agilent Technologies, Inc. ( A ) Bank of America Global Healthcare Conference 2025 September 25, 2025 4:50 AM EDT Company Participants Padraig McDonnell - CEO, President & Director Conference Call Participants Michael Ryskin - BofA Securities, Research Division Presentation Michael Ryskin BofA Securities, Research Division I'm Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team based in New York.
While the top- and bottom-line numbers for Agilent (A) give a sense of how the business performed in the quarter ended October 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Agilent Technologies (A) came out with quarterly earnings of $1.59 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $1.46 per share a year ago.
Life sciences firm Agilent Technologies on Monday beat fourth-quarter revenue estimates, helped by strong demand for medical tools and equipment used in lab research and diagnostic services.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Beyond analysts' top-and-bottom-line estimates for Agilent (A), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended October 2025.
Evaluate Agilent's (A) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
A posts fiscal Q3 earnings and revenue beats, with double-digit sales growth and upbeat guidance lifting shares.
Besides Wall Street's top-and-bottom-line estimates for Agilent (A), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended July 2025.
Most MoPay equities and funds offer annual dividends from a $1K investment that exceed their share price, presenting affordable but volatile opportunities. Analyst estimates suggest the top ten MoPay stocks could generate 16% to 104% total returns by August 2026, with an average gain of 30.56%. The 'dogcatcher' strategy identifies high-yield, contrarian picks, but emphasizes caution due to volatility, dividend cuts, and negative free cash flow in some names.